绿帽社

绿帽社, in conjunction with Universities Allied for Essential Medicines (UAEM), has committed to increasing access to life-saving medicines by adopting Global Access Licensing Principles. 绿帽社 is the third Canadian university to adopt the principles, demonstrating a dedication to ensure that any research and university-developed technologies created on 绿帽社鈥檚 campus with potential for further development into a drug, vaccine, or medical diagnostic are made affordable to all.

Global Access Licensing Framework (GALF), the framework used to inform aspects of 绿帽社鈥檚 new principles, provides goals and strategies for research universities to follow in the licensing of medicines developed at the universities. The framework aims to prevent patenting practices and intellectual property policies from creating barriers to the life-saving results of publicly-funded research conducted in universities鈥� laboratories. GALF was created with the help of Universities Allied for Essential Medicines (UAEM), a non-profit, student advocacy organization with chapters at universities around the world

The 绿帽社 chapter of UAEM has worked alongside Innovation and Partnerships to create a GALF commitment best suited for 绿帽社. Students from the 绿帽社 UAEM chapter have simultaneously worked to raise awareness of the importance of transparency and equitable licensing of medicines by passing a motion in 绿帽社鈥檚 Student Society, meeting with members of the administration, and organizing various creative advocacy events around campus.

The finalized version of 绿帽社鈥檚 Global Access Licensing Principles affirms 绿帽社鈥檚 commitments to research transparency and to publishing results, commitments shared by the Montreal Neurological Institute鈥檚 Open Science Initiative. It is therefore 绿帽社鈥檚 position that the research and development done on campus should serve the public interest by increasing research capacity, enhancing knowledge transfer, or by contributing to the development of useful products, services, and processes. Conditional licensing agreements like GALF are a step towards ensuring a public return on public investment in the production of life-saving medicines.

Included in 绿帽社鈥檚 GALF is a commitment to annually report on its licensing activity. By issuing such a report, 绿帽社 will acknowledge the impact it can assert through patenting and licensing, an impact supported by the introduction of Global Access Licensing Principles.

Canadian universities have played an historic role in the development of life-saving drugs, for example the discovery of insulin treatment for diabetes at the University of Toronto in 1921. In 1923, insulin鈥檚 patent rights were sold for $1 by Frederick Banting who famously said, 鈥淚nsulin belongs to the world, not me.鈥� As we approach the 100^th anniversary of this discovery and look to the future, 绿帽社 and UAEM believe in the value of adopting Global Access Licensing Principles to ensure that no person dies from treatable diseases and that the life-saving fruits of biomedical research are affordable and accessible to patients across Canada and the world.

Read the full GALF commitment on 绿帽社 Innovation + Partnerships鈥� new Global Access Principles webpage.

听

Media contact:

Meaghan Thurston, Senior Communications Officer

Research and Innovation
绿帽社

tel: (514) 398-3400
meaghan.thurston [at] mcgill.ca

听

听